• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 24th November 2015

How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards

A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework. Real world data (RWD) is a term that is becoming increasingly widespread in health economics and health…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
24-Nov-Lilly-RWE-blog-V2

A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework.

Real world data (RWD) is a term that is becoming increasingly widespread in health economics and health services research – with good reason. RWD is information that can be used for health care decision-making which is collected outside of an experimental clinical trial setting. RWD therefore has the benefit of reflecting outcomes in the “real-world”, i.e. routine clinical practice. 

The environment for collecting data alongside clinical practice and using it to support decision-making by regulators and payers is changing. Regulatory flexibilities and increasing public pressure to facilitate earlier access to medicines (e.g. through adaptive pathways or early access schemes) means that regulators are increasingly monitoring benefits and risks throughout a medicine’s lifecycle; RWD is essential to support this. 

Payers are similarly being challenged to conduct earlier value assessments under greater uncertainty, and re-visiting assessments as further RWD is collected. Moreover, managed entry agreements and arrangements for performance-based payments require data to be collected alongside clinical practice. These themes are central to the Accelerated Access Review currently being conducted by the UK’s Department of Health. 

Supporting all of these developments is the improving infrastructure across the globe for data collection, for example through electronic health records. However, in order to utilise and derive value from RWD, appropriate and facilitative information governance is essential. RWD becomes real world evidence (RWE) – what is really of value to stakeholders – after a series of activities which facilitate the transformation of raw data into analysis and results. Robust and proportionate data governance, applied at each step, is essential in realising the value of RWD. 

Figure 1: Value chain for generating Real World Evidence

OHE Consulting has just published a Consulting Report, commissioned by Lilly, which assesses the core governance arrangements for how RWD (both routinely-collected and de-novo) is accessed or generated, and used credibly to provide evidence in eight countries: the UK, France, Italy, Sweden, Germany, the Netherlands, Australia and the U.S. In our recommendations we focus on the first four steps of the value chain set out in Figure 1. By analysing the current state-of-play in each country, we propose an aspirational governance framework that could guide the management of data access and use, and facilitate constructive interactions among the relevant stakeholders. 

Governance arrangements for health data have at their core the need to balance public and privacy interests, of advancing our understanding of medical treatments through evaluation and research, on the one hand, and protecting individuals’ privacy, on the other. Different countries have different ways of addressing this aim. In most cases the legal framework in place to protect patient data is not completely prescriptive, making a clear governance framework all the more important. 

We find that appropriate and facilitative information governance, along with public trust, is key to realising the benefits of scientific research. Along with sophisticated and transparent approaches to data linkage, patient consent has a key role to play, alongside mechanisms for anonymisation and authorisation. For example, where data collection is on a routine basis across a large patient cohort, an opt-out system of patient consent may be appropriate. Data can be de-identified by removing any personally identifiable information and replacing the unique patient identifier with a pseudonym. 

By outlining the individual aspects and actions of an ideal framework for data governance, the authors assess the extent to which each of the countries analysed currently meets these criteria. The resulting set of recommendations work towards setting out international standards for a more facilitative environment for the transformation of RWD into RWE.

Access the full report here.

For more information contact Amanda Cole at OHE.

  • Drug Development/R&D
  • Economics of Innovation
  • Consulting Reports

Related News

  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!